Introducing the Adcendo leadership team

The Adcendo leadership team gathers decades of pre-clinical & clinical development experience including regulatory, CMC and commercial from larger pharma and dedicated biotech companies, as well as a track record of development of 8 of the currently approved ADCs.

Michael Pehl, MSc

Chief Executive Officer

+25 years of global pharmaceutical & biotech leadership experience. Former CEO of GEMoaB, CEO of Immun-omedics, and President of Hematology & Oncology at Celgene

Lone H. Ottesen, MD, PHD

Chief Medical Officer

+20 years of experience in Clinical Development focused on Oncology. Global development expertise spans small molecules, ADCs, immune therapies and epigenetic modulators across development phases; led several Global Clinical
Development teams at AstraZeneca, Early Oncology Development at Eisai and held various medical lead roles at GSK Oncology

Dominik Mumberg, PhD

Chief Scientific Officer

+25 years of experience in therapeutic innovation, translational sciences, pre-clinical and clinical development in oncology at Bayer & Schering. Former VP, Oncology Research, and Translational Innovation Lead, with focus on ADCs, radiotherapies & targeted therapies

Pernille Hemmingsen, PhD

Chief Technology Officer

+20 years of experience in the pharmaceutical industry. Former VP, Global Product Development and Supply at Savara ApS. 5 years at Genmab, leading ADC CMC and manufacturing, from non-clinical to phase II development

Carmel M. Lynch, PhD

Chief Development Officer

+25 years of experience in biotechnology, spanning from discovery research to clinical development, with an emphasis on translational medicine. +15 years specializing in ADCs; led Nonclinical and Clinical Pharmacology development of Adcetris ADC at SeaGen from pre-IND to approval in 2011

James Wang, PhD

VP, Head of Business Development

+10 years of consulting and global biopharmaceutical experience across strategy and business development. Former Senior Director BD at Innovent, Head of Search & Evaluate Immunology at Simcere and Associate Director Global Product & Portfolio Strategy at AstraZeneca

Margaret McNaull, BSc, MBA

VP, Head of Clinical Development

+25 years global pharmaceutical experience. Global development expertise spanning small molecules, ADCs, immune therapies and biosimilars covering early phase development to post launch. Headed AstraZeneca Project Management Centre of Excellence, led Clinical Operations across multiple late development programmes including regulatory submissions and approvals

Victoria Marsh, PhD

VP, Head of regulatory and Safety

+18 years of regulatory experience with an emphasis on oncology and rare diseases. Global Regulatory Lead for a range of small molecules, biologics and advanced therapies from early development to market approvals. Former Executive Director at AVROBIO, Senior Director at MedImmune/AstraZeneca and regulatory consultant

Christoffer Nielsen, PhD

VP Operations, General Manager & Co-founder

As a molecular biologist by training, Chris conducted the post doc project at The University of Copenhagen and Rigshospitalet, which laid the foundation for creating the spin-out Adcendo in 2017. Having been at the forefront of managing and expanding Company operations since day one, Chris today serves as VP Operations
and General Manager

Mikkel Krogh-Madsen, PhD

ED, Head of Portfolio & Programme Management

+15 years of experience in the pharmaceutical industry and oncology/hematology hospital setting. Extensive tenure at LEO Pharma as Global Project Director across clinical phases and part of Development leadership team, Head of CMC departments, and Analytical Scientist

Lasse René Sørensen

Senior Director, Head of ESG and Finance

+10 years of experience at Deloitte's consulting practice, Lasse has honed his expertise in Accounting and Reporting Advisory, guiding organizations through complex financial landscapes. His work has primarily focused on disruptive events, including M&A activities and IPO journeys, where he has played a pivotal role in ensuring seamless transitions and robust financial reporting